Atara Biotherapeutics(ATRA)（納斯達克股票代碼：ATRA）報告稱，季度每股虧損$(1.19)，優於分析師一致預期的$(3.58)，提升了66.76%。與去年同期每股虧損$(14.00)相比，這是一個91.5%的增長。公司報告季度銷售額爲$32.753M，未達到分析師一致預期的$19.148M，同比增長100%。相比去年同期的銷售額$4.252M，這是一個100%的下降。

以上內容來自Benzinga Earnings專欄，原文如下：

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of $(3.58) by 66.76 percent. This is a 91.5 percent increase over losses of $(14.00) per share from the same period last year. The company reported quarterly sales of $32.753 which missed the analyst consensus estimate of $19.148 million by 100.00 percent. This is a 100.00 percent decrease over sales of $4.252 million the same period last year.